Dr Habeebullah Life Sciences Ltd
BSE:539267
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
D
|
Dr Habeebullah Life Sciences Ltd
BSE:539267
|
408.1m INR |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
189.6B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
149.1B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
46.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.6B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
292.3B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
35.6B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.4B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.9B USD |
Loading...
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
163.2B HKD |
Loading...
|
Market Distribution
Other Profitability Ratios
Dr Habeebullah Life Sciences Ltd
Glance View
Dr Habeebullah Life Sciences Ltd. is an India-based company. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2015-08-10. The firm is engaged in research and development (R&D), trading, import and exports, and R&D services of bioproducts and pharma products. The firm's products and R&D include Stem Cell R&D, New Drug Discovery, ribonucleic acid (RNA) Interference, Molecular Biomarkers and Medical Devices. Its Stem Cell R&D division specializes in stem cell research and therapy, regenerative medicine, bio-artificial organ scaffolds development, nanobiotechnology, nano formulation of cancer drugs, molecular genetics, and molecular virology, stem cell and cord blood banking. Its New Drug Discovery division is focused on working on five therapeutic areas of Wilson’s disease, non-alcoholic steatohepatitis (NASH), neuropathic pain, cardiovascular diseases, cystinosis and Huntington's disease. Its services include molecular diagnostics, stem cell therapy, clinical services, contract research organization and academic services.
